A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.

AbbVie291 enrolled

Overview

This study will describe historic, current, and evolving treatment pathways, treatments, and interventions in women with a suspected or confirmed diagnosis of endometriosis in order to better understand the impact of early intervention on the disease or its symptoms. Length of treatment is dependent on standard of care treatment provided and all study information will be collected during routine standard of care visits.

Study Type

OBSERVATIONAL

Enrollment

291

Conditions

Endometriosis Chronic Pelvic Pain Dysmenorrhea

Eligibility

Sex: FEMALEMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women of reproductive age (between their first menstrual cycle and before onset of menopause). * Women who have experienced chronic pelvic pain (CPP) and/or dysmenorrhea (DYS) for at least 6 months prior to enrollment without symptom improvement with non-steroidal anti-inflammatory drugs (NSAIDs) or hormone/medical treatment. * Women with suspected or confirmed endometriosis (EM) at time of enrollment. * Women with CPP and/or DYS impacting daily activities as determined by their treating physician. * Able to read, understand and respond to patient questionnaires. * Willing to sign a patient authorization and/or informed consent form (ICF) and agree to disclose personal health information. NOTE: For pediatric patients, parental/guardian assent/ICF is also required. Exclusion Criteria: * Women with chronic pelvic pain (CPP) and/or dysmenorrhea(DYS) for reasons other than endometriosis (EM). * Women who have had a hysterectomy and/or bilateral ovary removal (oophorectomy). * Women who are pregnant or planning to become pregnant. * Women currently using assisted reproductive technologies such as in vitro fertilization (IVF). * Women with a history of, or current malignancy (with or without systemic chemotherapy) with the exception of basal cell carcinoma of the skin. * Women who are currently participating in an interventional clinical trial.

Locations (117)

University of Alabama at Birmingham - Women's and Infant's Center /ID# 216236

Birmingham, Alabama, United States

Atlanta VAMC /ID# 215763

Decatur, Alabama, United States

Brown, Pearson, Guepet Gynecology /ID# 215500

Fairhope, Alabama, United States

Women's Health Alliance of Mobile /ID# 213719

Mobile, Alabama, United States

Mobile, Ob-Gyn, P.C. /ID# 217761

Mobile, Alabama, United States

Outcomes

Primary Outcomes

Percentage of participants using specific medications for the treatment of chronic pelvic pain (CPP) and/or dysmenorrhea (DYS)

Data regarding medication use for CPP and/or DYS will be collected from participant medical records, health care provider questionnaires, and participant completed questionnaires.

Time frame: From onset of CPP and/or DYS to up to 4 years following study enrollment.

Percentage of participants who underwent surgical interventions for the treatment of CPP and/or DYS

Percentage of participants who underwent surgical interventions for the treatment of CPP and/or DYS at any point from onset of CPP and/or DYS and study completion.

Time frame: From onset of CPP and/or DYS to up to 4 years following study enrollment.

Number of surgical interventions for the treatment of CPP and/or DYS

Number of surgical interventions for the treatment of CPP and/or DYS.

Time frame: From onset of CPP and/or DYS to up to 4 years following study enrollment.

Percentage of participants undergoing hysterectomy

Percentage of participants undergoing hysterectomy during study enrollment.

Time frame: From study enrollment (Week 0) to up to 4 years.

Percentage of participants undergoing infertility treatment

Percentage of participants undergoing infertility treatments during study enrollment.

Time frame: From study enrollment (Week 0) to up to 4 years.

Percentage of participants undergoing surgery

Percentage of participants undergoing surgery as treatment for CPP and/or DYS.

Time frame: From study enrollment (Week 0) to up to 4 years.

Percentage of participants with complications associated with surgery

Percentage of participants with complications associated with surgery.

Time frame: From study enrollment (Week 0) to up to 4 years.

Percentage of participants receiving specific treatment sequences for the treatment of CPP and/or DYS

Treatment sequences will be identified from the data. Treatment switching, add-on treatment, and discontinuations (including reasons) will be collected wherever possible.

Time frame: From onset of CPP and/or DYS to up to 4 years following study enrollment.